88 related articles for article (PubMed ID: 3651380)
1. Ocular toxicity of anandron.
Brisset JM; Bertagna C; Proulx L
Br J Ophthalmol; 1987 Aug; 71(8):639-40. PubMed ID: 3651380
[No Abstract] [Full Text] [Related]
2. Ocular toxicity of Anandron in patients treated for prostatic cancer.
Harnois C; Malenfant M; Dupont A; Labrie F
Br J Ophthalmol; 1986 Jun; 70(6):471-3. PubMed ID: 3718913
[TBL] [Abstract][Full Text] [Related]
3. [Fatal fulminant hepatitis induced by nilutamide (Anandron)].
Pescatore P; Hammel P; Durand F; Bertheau P; Bernuau J; Huc D; Gerbal JL; Degott C; Benhamou JP
Gastroenterol Clin Biol; 1993; 17(6-7):499-501. PubMed ID: 8243938
[TBL] [Abstract][Full Text] [Related]
4. Comment: clinical experiences of visual disturbances with nilutamide.
Dijkman GA; Klotz LH; Diokno AC; Zippe CD
Ann Pharmacother; 1997 Dec; 31(12):1550-2. PubMed ID: 9416403
[No Abstract] [Full Text] [Related]
5. [Pulmonary toxicity of nilutamide (Anandron). Cooperative evaluation of French Regional Pharmacovigilance Centers].
Jonville AP; Diot E; Dutertre JP; Autret E
Therapie; 1992; 47(5):393-7. PubMed ID: 1299978
[TBL] [Abstract][Full Text] [Related]
6. Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo.
Brisset JM; Boccon-Gibod L; Botto H; Camey M; Cariou G; Duclos JM; Duval F; Gontiès D; Jorest R; Lamy L
Prog Clin Biol Res; 1987; 243A():411-22. PubMed ID: 3309973
[No Abstract] [Full Text] [Related]
7. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report.
Gomez JL; Dupont A; Cusan L; Tremblay M; Tremblay M; Labrie F
Am J Med; 1992 May; 92(5):563-6. PubMed ID: 1580304
[TBL] [Abstract][Full Text] [Related]
8. Delayed dark adaptation caused by nilutamide.
Chan P; Odel JG
J Neuroophthalmol; 2008 Jun; 28(2):158-9. PubMed ID: 18562852
[No Abstract] [Full Text] [Related]
9. Antiandrogen withdrawal syndrome with nilutamide.
Gomella LG; Ismail M; Nathan FE
J Urol; 1997 Apr; 157(4):1366. PubMed ID: 9120950
[No Abstract] [Full Text] [Related]
10. Nilutamide-induced neutropenia.
Eaton VS; Blackmore TK
BJU Int; 2001 Nov; 88(7):801-2. PubMed ID: 11890258
[No Abstract] [Full Text] [Related]
11. [Fatal fulminating hepatitis caused by nilutamide. A new case].
Marty F; Godart D; Doermann F; Mérillon H
Gastroenterol Clin Biol; 1996; 20(8-9):710-1. PubMed ID: 8977826
[No Abstract] [Full Text] [Related]
12. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
Boccardo F; Decensi AU; Guarneri D; Martorana G; Fioretto L; Mini E; Macaluso MP; Giuliani L; Santi L; Periti P
Cancer Detect Prev; 1991; 15(6):501-3. PubMed ID: 1782640
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics of a new antiandrogen Anandron (RU 23908).
Pendyala L; Creaven PJ; Huben R; Tremblay D; Mouren M; Bertagna C
Prog Clin Biol Res; 1987; 243A():351-63. PubMed ID: 3659005
[No Abstract] [Full Text] [Related]
14. [Indications of antiandrogens in benign hyperplasia of the prostate].
Benassayag E
J Urol (Paris); 1995; 101(2):109-10. PubMed ID: 8522854
[No Abstract] [Full Text] [Related]
15. Design of antiandrogens and their mechanisms of action: a case study (anandron).
Raynaud JP; Fiet J; Le Goff JM; Martin PM; Moguilewsky M; Ojasoo T
Horm Res; 1987; 28(2-4):230-41. PubMed ID: 3331376
[TBL] [Abstract][Full Text] [Related]
16. [The antiandrogen treatment of patients with prostatic cancer and bone metastases].
Matveev BP; Bukharkin BV; Zhumagazin ZhD
Urol Nefrol (Mosk); 1993; (1):10-4. PubMed ID: 7941115
[TBL] [Abstract][Full Text] [Related]
17. Reduction in undesired sexual hair growth with anandron in male-to-female transsexuals--experiences with a novel androgen receptor blocker.
Asscheman H; Gooren LJ; Peereboom-Wynia JD
Clin Exp Dermatol; 1989 Sep; 14(5):361-3. PubMed ID: 2612040
[TBL] [Abstract][Full Text] [Related]
18. [Therapy of metastatic prostatic cancer by orchiectomy plus Anandron versus orchiectomy plus placebo. Initial results of a randomized multicenter study].
Knönagel H; Bolle JF; Hering F; Senn E; Hodel T; Neuenschwander H; Biedermann C
Helv Chir Acta; 1989 Aug; 56(3):343-5. PubMed ID: 2681086
[TBL] [Abstract][Full Text] [Related]
19. Total androgen ablation in the treatment of metastatic prostatic cancer. The Canadian Anandron Study Group.
Semin Urol; 1990 Aug; 8(3):159-65. PubMed ID: 2204980
[No Abstract] [Full Text] [Related]
20. A comparison of the treatment of metastatic prostate cancer by testicular ablation or total androgen blockade. The Canadian Anandron Study Group.
Cancer Treat Res; 1992; 59():29-40. PubMed ID: 1347692
[No Abstract] [Full Text] [Related]
[Next] [New Search]
